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Despite improvements in early diagnosis and treatment, breast cancer is still a major
health problem worldwide. Among breast cancer subtypes, the most challenging and
harder to treat is represented by triple-negative molecular subtype. Due to its intrinsic
features this subtype cannot be treated neither with hormonal therapy (since it does not
express estrogen or progesterone receptors) nor with epidermal growth factor receptor 2
(HER2) inhibitors (as it does not express high levels of this protein). For these reasons, the
standard of care for these patients is represented by a combination of surgery, radiation
therapy and chemotherapy. In this scenario, searching for novel biomarkers that might
help both in diagnosis and therapy is mandatory. In the last years, it was shown that
different families of potassium channels are overexpressed in primary breast cancers. The
altered ion channel expression may be useful for diagnostic and therapeutic purposes due
to some peculiar characteristics of this class of molecules. Ion channels are defined as
pore-forming transmembrane proteins regulating passive ion fluxes in the cells. Ion
channels represent good potential markers since, being localized at the plasma
membrane level, their detection and block with specific drugs and antibodies might be
fast and tunable. This review focuses on triple-negative breast cancers and recapitulates
the current knowledge about potassium channels' clinical relevance and their potential
use in the clinical setting, for triple-negative breast cancer diagnosis and therapy.
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Breast cancer (BC) is a heterogeneous disease composed of different molecular subtypes, with
peculiar histopathological and biomolecular features. Currently BC classification relies on the
detection of four biomarkers: estrogen receptor (ER), progesterone receptors (PgR), human
epidermal growth factor receptor 2 (HER2), and the proliferation index (Ki67 staining).
Applying such molecular classification, five main BC subtypes with different features and
prognosis can be defined: Luminal A, Luminal B, HER2-positive, triple-negative (TNB), and
normal-like. Among BC subtypes, the most challenging and harder to treat is represented by triple-
negative BC (TNBC) (Santana-Davila and Perez, 2010; Penault-Llorca and Viale, 2012).
In this scenario, searching for novel biomarkers that might help clinicians in BC management
appears to be mandatory. Mounting evidences gathered in the last 20 years pointed out that severalin.org May 2020 | Volume 11 | Article 7251
Lastraioli K+ Channels in TNBCion channels might represent biomarkers, since their expression
is frequently dysregulated in BC and association with clinico-
pathological features have been described for some of them.
The aim of the present review is to summarize the current
knowledge about potassium channels relevance in BC with a
special focus on their role in treatment and patients' outcome.CLINICAL FEATURES OF TNBC
According to data recently published by the American Cancer
Society (American Cancer Society, 2017), TNBC accounts for
12% of all BC. Its incidence is higher in young patients, in
subjects carriers of BRCA1 mutations (Perou and Børresen-Dale,
2011) and of particular ethnicity (African American and
Hispanic women are at higher risk with respect to Caucasians)
(Millikan et al., 2008). TNBC patients generally have a bad
prognosis since their tumors are often bigger, classified as G3
and with lymphnode involvement (Dent et al., 2007). The main
features of TNBCs are summarized in Table 1.HISTOPATHOLOGY OF TNBC
From a histopathological point of view, most TNBC are classified
as invasive ductal carcinomas of no special type (Carey et al.,
2006) that could display basal-like features or not. A minor part
of TNBC belongs to rare histological types such as atypical or
typical medullary-like (Jacquemier et al., 2005; Livasy et al.,
2006), apocrine carcinomas and pleomorphic lobular
carcinomas (Kreike et al., 2007), metaplastic carcinomas
(Livasy et al., 2006; Reis-Filho et al., 2006), and adenoid cystic
carcinomas (Cleator et al., 2007). Among them, it was shown that
metaplastic and medullary-like cancers display basal-like
features that are uncommon in the other histotypes
(Jacquemier et al., 2005; Bertucci et al., 2006; Rodriguez-Pinilla
et al., 2007). Three representative pictures of TNBC of different
histotype are reported in Figure 1.
As summarized in Table 1, TNBC are frequently associated
with aggressive histopathological characteristics such as an
abundant lymphocytic infiltrate and central necrotic area, high
grading (either nuclear and histological), high mitotic rate,
presence of pushing margins and altered nuclear-cytoplasmatic
ratio (Tot, 2000; Fulford et al., 2006; Livasy et al., 2006; Bauer
et al., 2007; Kreike et al., 2007; Millikan et al., 2008; Sasa et al.,
2008; Kaplan et al., 2009).BIOMOLECULAR FEATURES OF TNBC
Since the terms “TNBC” and “Basal-like” are not synonymous,
although they share many common features, a thorough analysis
of a great cohort of samples in the METABRIC study according
to PAM50 (Curtis et al., 2012; Engebraaten et al., 2013) was
performed: such analysis showed that most TNBC are classifiedFrontiers in Pharmacology | www.frontiersin.org 2as Basal-like (86.1%) but also other subtypes such as HER2-
enriched, normal-like and Luminal A are represented.
The gene expression analysis of the same cohort showed that
the higher percentage of basal-like tumors do not express ER,
PgR and HER2 (and are therefore defined as triple negative), but
there are also samples expressing either ER or HER2. Due to the
discrepancy between the two classifications, several efforts have
been made to provide a more precise classification using
immunohistochemical markers such as cytokeratin and EGFR
(see also Table 1) (Nielsen et al., 2004; Carey et al., 2006; Blows
et al., 2010; Broeks et al., 2011).TNBC TREATMENT
As stated before, TNBC represent the most difficult to treat due
to the absence of good targets such as hormone receptors or
other molecules to be specifically targeted with effective drugs. A
recent review (Yu et al., 2020) described some novel potential
targets such as gene targets, Noncoding RNA, classical signaling
pathways among others. From a clinical point of view, in 2017
the Food and Drug Administration (FDA) approved the use of
cyclin-dependent kinases 4/6 (CDK4/6) inhibitors (ribociclib,May 2020 | Volume 11 | Article 725TABLE 1 | Triple-negative breast cancer (TNBC) characteristics.
CHARACTERISTIC TNBC Basal-like BC
Age of Onset <50 years <50 years








































































NoER, estrogen receptor; PgR, progesterone receptor; CK, cytokeratin; EGFR, epidermal
growth factor receptor; —, negative by definition; –, almost always negative; -, usually
negative; +, usually positive; ++, almost always positive.
Lastraioli K+ Channels in TNBCpalbociclib, abemaciclib) for ER+ and HER2- advanced BC
(Eggersmann et al., 2019). In the following year, also PARP
inhibitors (talazoparib, olaparib) were approved for HER2- and
BRCA1/2-mutant advanced BC (McCann and Hurvitz, 2018).POTASSIUM CHANNELS
Ion channels have been proven to be expressed in human tumors
of different origin and it was shown that they act in different
manners, modulating several key cell processes. For these
reasons, ion channels could represent novel cancer biomarkers,
once properly validated in the clinical setting. Being localized in
the plasma membrane, ion channel detection might be easily
performed by IHC and molecular techniques thus raising the
possibility of quick detection of the protein; moreover, for the
same reason, they represent a good potential target for therapy
with specific drugs and antibodies.Frontiers in Pharmacology | www.frontiersin.org 3Potassium channels are a multi-gene family composed of
several subfamilies (Figure 2): voltage-gated potassium channels,
inward rectifiers, two-pore domains and calcium-activated
channels (reviewed in D'Amico et al., 2013). In Voltage-gated
potassium channels four subunits surround an aqueous pore:
each subunit is composed by six transmembrane domains (S1–
S6), of which S4 represents the voltage sensor while the pore (P)
is defined by a loop between S5 and S6. The channels belonging
to the Inward rectifiers subfamily are composed of four subunits,
each with two transmembrane domains linked by a P-loop.
Channels classified as Two-pore domains are characterized by
four transmembrane domains and an aqueous pore formed by
two regions. Another subfamily is represented by Calcium-
activated potassium channels: these channels belong to two
groups of proteins named “small- and intermediate-
conductance” (SK) and “high-conductance” potassium
channels (BK). The former are tetramers composed by six
transmembrane domains (S1–S6) each with the central poreFIGURE 2 | Classification and molecular structure of potassium channels.FIGURE 1 | Representative pictures of three triple-negative breast cancer (TNBC) samples of different histotype stained with Hematoxylin & Eosin. Bar: 100µm.
(A) invasive ductal carcinoma; (B) invasive metaplastic carcinoma-spindle cell subtype; (C) invasive lobular carcinoma.May 2020 | Volume 11 | Article 725
Lastraioli K+ Channels in TNBClocated in the S5-S6 region; the latter are tetramers made of a
and b subunits in which the pore is formed by a subunits.POTASSIUM CHANNELS IN BC
It is well known that that ion channels are aberrantly expressed
in different tumors (see, for example, the review by Lastraioli
et al., 2015a). Among them, potassium channels have been
shown to be overexpressed in primary BCs and cell lines
(reviewed in Lastraioli, 2018). In Table 2, a detailed list of the
potassium channels whose expression has been described in BC
are reported.
Kv1.3 channels, are members of the voltage-gated family,
encoded by KCNA3 gene. It has been shown that Kv1.3 channels
have a key role in several cell processes such cell proliferation,
apoptosis, setting the cell resting membrane potential and
regulating cell volume (Cahalan and Chandy, 2009; Teisseyre
et al., 2015). Kv1.3 channels have been shown to be associated
with poor prognosis in BC patients (Jang et al., 2009). The
expression of Kv1.3 mRNA and the corresponding protein was
proven to be reduced in grade III BC and an inverse association
with tumor grade and advanced stage (Brevet et al., 2009)
emerged. The same Authors, demonstrated that the
methylation of the promoter of the gene increased in grade III
tumors (thus decreasing KCNA3 transcription) and it is
associated with poor differentiation and younger age of the
patients (Brevet et al., 2009). Recently, the potential use of
Kv1.3 for cancer diagnostic and therapy has been reviewed
(Teisseyre et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 4Kv10.1 (Eag1 or KCNH1) is a voltage-gated potassium
channel encoded by the KCNH1 gene. In physiological
conditions, Kv10.1 channels are expressed mainly in brain,
adrenal gland, myoblasts, placenta and testis (Bijlenga et al.,
1998; Ouadid-Ahidouch et a l . , 2016) . In exci table
tissues (muscle and brain) Kv10.1 channel sustains
hyperpolarization and controls neuronal excitability
(Ouadid-Ahidouch et al., 2016). Nevertheless, Kv10.1
expression has been described also in several human
tumors at difference from the corresponding normal tissues
both at the mRNA and protein level (Hemmerlein et al.,
2006). High Kv10.1 protein levels have been found in human
BCs (Hemmerlein et al., 2006; Garcı ́a-Becerra et al., 2010)
and it was shown that Kv10.1 expression is higher in
invasive-ductal carcinomas than in fibroadenomas (Garcıá-
Becerra et al., 2010). More interestingly, Kv10.1 is highly
expressed in TNBCs with respect to other molecular subtypes
and it was shown that it is associated with tumor stage, size,
and lymph node involvement (Liu et al., 2015). In BC cell
lines it was shown that the combination of Astemizole
(Kv10.1 blocker) and gefitinib (EGFR inhibitor) have a
synergic effect in impairing proliferation in BC cells
expressing both proteins (Garcı ́a-Quiroz et al., 2019a). The
same Author also showed that the combined treatment with
calcitriol and curcumin or resveratrol had a synergistic effect
both in vitro and in vivo in human mammary tumor cells
(Garcı ́a-Quiroz et al., 2019b).
Kv11.1 (also named hERG1) encoded by KCNH2 gene, is
another member of the voltage-gated family that has been








Voltage-gated KCNA3 Kv1.3 MK3, HLK3,
HPCN3
KCNA3 Poor prognosis (Brevet et al., 2009), advanced stage, younger age (Jang et al., 2009)
KCNH1 Kv10.1 eag1 KCNH1 Overexpression (Hemmerlein et al., 2006), correlation with vitamin D receptor in invasive
ductal carcinomas (Garcıá-Becerra et al., 2010), poor prognosis, high expression in TNBC,
association with stage, positive lymph nodes, higher expression in invasive ductal carcinomas
(Liu et al., 2015)
KCNH2 Kv11.1 hERG1 KCNH2 KCNH2 gene overexpression (Fukushiro-Lopes et al., 2017), correlation with molecular
subtype, grading, ER, ki67 (Iorio et al., 2018), relapse (Breuer et al., 2019)
Inward Rectifier KCNJ3 Kir3.1 GIRK1, KGA KCNJ3 Lymph node metastases, association with ER, independent prognostic factor (OS and DFS)
(Kammerer et al., 2016)
Two-pore
domain
KCNK5 K2p5.1 TASK-2, TASK2,
KCNK5b
KCNK5 Overexpression (Dookeran et al., 2017)
KCNK6 K2p6.1 KCNK8, TOSS,
TWIK-2, TWIK2
KCNK6 Downexpression (Dookeran et al., 2017)
KCNK9 K2p9.1 KT3.2, TASK-3,
TASK3
KCNK9 Gene amplification (Mu et al., 2003; Lee et al., 2012), Overexpression (Dookeran et al., 2017)





KCNK15 Downexpression (Dookeran et al., 2017)
Calcium-
activated
KCNMA1 KCa1.1 mSLO1 KCNMA1 High stage, high grade, proliferation, poor prognosis (Oeggerli et al., 2012), brain metastases
(Khaitan et al., 2009)
KCNN4 KCa3.1 hSK4, hKCa4,
hIKCa1
KCNN4 High grade with negative lymph nodes (Haren et al., 2010); poor prognosis (Faouzi et al.,
2016)May 2020 | Volume 11 | Article 725
Lastraioli K+ Channels in TNBCet al., 2015b) and also in BC (Fukushiro-Lopes et al., 2017;
Iorio et al., 2018). Through the analysis of public datasets, it
was demonstrated that KCNH2 gene is overexpressed in BC
(Fukushiro-Lopes et al., 2017). We recently showed that
Kv11.1 protein expression in primary BCs is associated with
molecular subtype (Iorio et al., 2018). In particular, we
showed that Kv11.1 scoring was higher in Luminal A
(tumors expressing ER, PgR, negative for HER2 expression,
with a low proliferation index evaluated through Ki67
expression), progressively decreasing in Luminal B (tumors
expressing ER, PgR, positive, or negative for HER2 expression,
with a high proliferation index), HER2+ (tumors with high
HER2 expression, low or absent ER and PgR and low Ki67)
and TNBC tumors (Iorio et al., 2018). Moreover, considering
all the molecular subtypes it emerged that patients with high
Kv11.1 protein expression have a longer Progression-Free
Survival and the same trend was observed for Local Relapse
Free-Survival and Metastases-Free Survival (Iorio et al., 2018).
A recent meta-analysis focused on KCNH2 gene expression
confirmed our data, showing that high expression of the gene
was associated with longer relapse-free survival (Breuer et al.,
2019) and more interestingly, the association was restricted to
ER-negative patients.
The inward rectifier Kir3.1 (also named KCNJ3) encoded
by KCNJ3 gene, is positively associated with the development
of nodal metastases (Stringer et al., 2001). The same channel
was proven to be associated with ER expression and its
expression was demonstrated to be an independent indicator
of poor prognosis in ER-expressing tumors (Kammerer
et al., 2016).
Several channels belonging to the two-pore subfamily have
been shown to be aberrantly expressed in BCs. The KCNK9 gene
encoding for K2P9.1 (also indicated as KCNK9 or TASK3), has
been shown to be amplified in BC and the corresponding channel
is overexpressed (Mu et al., 2003; Lee et al., 2012). Moreover,
KCNK9 mediates cell migration in BC cell lines (Lee et al., 2012).
More recently, a comprehensive analysis was performed in
TNBC databases of the TCGA (Dookeran et al., 2017): from such
analysis it was demonstrated that in TNBC molecular subtype
KCNK5, KCNK9, and KCNK12 are overexpressed while KCNK6
and KCNK15 are down-expressed. Moreover, alterations in CpG
island methylation were significantly associated with TNBC
subtype (Dookeran et al., 2017).
In primary BCs the expression of KCa1.1 (also named BK), a
member of Calcium-activated subfamily encoded by KCNMA1
gene, is associated with ER expression (Oeggerli et al., 2012), the
development of metastases in the brain (Khaitan et al., 2009),
nuclear grade, proliferation, stage and poor prognosis (Khaitan
et al., 2009). KCa1.1 was found to be expressed in different BC
subtypes and is blocked by Penitrem1 (Goda et al., 2018). The
expression of another member of the same family, KCa3.1 (also
named KCNN4 and encoded by the KCNN4 gene) was found to
be associated with high grade BCs without lymph nodes
involvement (Haren et al., 2010). Another report through the
analysis of public datasets highlighted the relevance of KCa3.1 inFrontiers in Pharmacology | www.frontiersin.org 5BC since it was shown that the mRNA levels were associated with
poor prognosis (Faouzi et al., 2016).POTASSIUM CHANNELS AS
THERAPEUTIC TARGETS
Several evidences have been gathered addressing the possibility
of using ion channels (and in particular potassium channels) as
therapeutic targets (reviewed in Arcangeli et al., 2009). A paper
published in 2003 (Abdul et al., 2003) and focused on Kv1.3
channels, demonstrated that potassium channel blockers such as
dequalinium and amiodarone significantly reduced MCF-7 BC
cells proliferation and increased the growth-inhibitory effects of
the anti-estrogen drug tamoxifen on BC cell lines, also those
derived from TNBC (MDA-MB231) (Abdul et al., 2003).
In another interesting paper it was shown that Penitrem 1 is
capable of blocking BK channels and that Penitrem A has a
synergistic antiproliferative effect with HER-targeting drugs
(Goda et al., 2018).
A member of the Calcium-activated subfamily, KCa3.1, was
found to promote the acquisition of radioresistance in BC cells
(Mohr et al., 2019), therefore it was suggested that targeting the
channel during radiation therapy could result in radiosensitization
of the tumor.
In vivo, it was shown that the Kv10.1 blocker astemizole
impaired MBCDF and T-47D cells xenografts growth (Garcıá-
Quiroz et al., 2019a). Moreover, the combined treatment with
astemizole and calcitriol caused a significant reduction of the T-
47D xenografts tumor masses as it happened in mouse models
obtained inoculating primary BCs (Garcıá-Quiroz et al., 2014).
The molecular bases of such effect were explained in a previous
paper of the same group (Garcıá-Quiroz et al., 2012): calcitriol has
an antiproliferative effect since it inhibits Kv10.1 (that modulates
cell cycle and tumor progression) while astemizole is a blocker of
Kv10.1 currents; the synergistic effects involve the downregulation
of Cytochrome P 24A1 (CYP24A1), upregulation of Vitamin D
Receptor (VDR) and Kv10.1 targeting. It was also demonstrated
that Chloroquine (a drug used for the treatment of malaria that
has been investigated also for its antitumoral effects) inhibited
Kv10.1 currents and reduced cell migration in MDA-MB-231 cells
(Valdés-Abadıá et al., 2019).
Kv11.1 was proven to be a potential therapeutic target in
several human solid cancers (Crociani et al., 2013; Crociani et al.,
2014; Lastraioli et al., 2015c; Iorio et al., 2020). Long ago, it was
demonstrated that Kv11.1 current was inhibited by tamoxifen
(Thomas et al., 2003) and more recently it was shown that such
inhibition is actually due to the active metabolite of tamoxifen,
named endoxifen (Chae et al., 2015).
In a paper published in 2011 it was shown that Arsenic
trioxide (a drug used to treat mainly promyelocitic leukemias but
also effective on solid tumors) induced apoptosis of MCF-7 BC
cells, through Kv11.1 inhibition (Wang et al., 2011). Another
paper from the same group confirmed such evidences in vivo, in
MCF-7 xenografts and also determined that the mechanismMay 2020 | Volume 11 | Article 725
Lastraioli K+ Channels in TNBCunderlying tumor growth inhibition was centered on a Kv11.1-
mir328 pathway (Wang et al., 2015). Recently it was shown that
small molecule activators of the Kv11.1 channel impair tumor
growth and metastasis in xenografts of TNBC (Breuer
et al., 2019).
More interestingly, the combination of specific channel blockers
along with drugs already in use in the clinical settings (such as
bevacizumab) was proven to be extremely effective since it was able
to significantly reduce in vivo tumor growth in mouse models
(Crociani et al., 2014). In a recent paper (Iorio et al., 2020), we
demonstrated that Kv11.1 (along with HIF2a) has a positive impact
on PFS of patients affected by metastatic colorectal cancer and
treated with bevacizumab and could therefore be used to identify
patients likely to benefit from the treatment. This finding could be of
particular interest also in BC treatment, since the approval to use
bevacizumab for metastatic BC patients was revoked by the FDA in
2011 due to the little improvement in favorable outcome considered
not sufficient. Nevertheless, a meta-analysis of randomized
controlled trials showed that the combination of chemotherapy
and bevacizumab significantly improved PFS of metastatic BC
patients and could therefore be used, once selected the optimal
target population (Li et al., 2015).
In a different setting (pancreatic ductal adenocarcinoma), we
found an association and a physical interaction between Kv11.1Frontiers in Pharmacology | www.frontiersin.org 6and EGFR, raising the possibility of designing combined
treatment schedules, also involving Kv11.1 blockers (Lastraioli
et al., 2015c). Also in this case, such therapeutic approach could
be applied to BC patients.CONCLUSIONS
TNBC is characterized by a poorer prognosis with respect to
other BC subtypes. Due to the absence of molecular markers
there is currently no targeted therapy and the gold standard of
therapy for TNBC is represented by chemotherapy. For these
reasons, searching for novel biomarkers and targets for TNBC is
mandatory. In this scenario, ion channels have a great potential
of representing potential biomarkers due to their localization
that allows an easy detection for diagnostic and prognostic
purposes and could also be easily blocked by specific drugs
and antibodies.AUTHOR CONTRIBUTIONS
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